Industry Information

Urofollitropin Instructions: Precautions during medication

  Urofollicle-stimulating hormone must only be used by a physician experienced in the treatment of infertility.

  A urofollicle-stimulating hormone can cause mild to moderate ovarian enlargement, which may be accompanied by abdominal distension and/or abdominal pain, which usually relieves within 2 to 3 weeks.

  A urofollicle-stimulating hormone can cause severe pulmonary complications (such as acute respiratory distress syndrome, exacerbation of asthma, etc.) and ovarian hyperstimulation syndrome, with rare reports of death.

Urofollitropin Instructions: Precautions during medication

  The urofollicle-stimulating hormone can lead to ovarian hyperstimulation syndrome, which progresses rapidly within 24 hours to several days in severe cases, manifested as a sharp increase in vascular permeability, resulting in rapid accumulation of fluid in the thoracic and peritoneal cavities, including the pericardium. Early symptoms include severe pelvic pain, weight gain, nausea, and vomiting. Ovarian hyperstimulation syndrome can occur at the end of treatment, and reach its peak in 7 to 10 days. Follow-up should be followed up for at least 2 weeks after treatment with urinary follicle-stimulating hormone, and it will automatically relieve menstrual cramps. Severe cases require drug withdrawal and hospitalization.

  Can cause multiple births, and patients should be informed before the treatment.

  The above is the relevant content of Urofollitropin Instructions. If you also have Human chorionic gonadotropin API Supplier, Human Menopausal Gonadotropin supplier, Urofollitropin price, Urokinase manufacturer, Hormone API Manufacturer, and other needs, you can directly contact Kangyuan by phone. We have many years of industry experience in R&D and production The trusted brand choice.